Cargando…

Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with PDL1 amplification

Identification of the tissue of origin in cancer of unknown primary (CUP) poses a diagnostic challenge and is critical for directing site-specific therapy. Currently, clinical decision-making in patients with CUP primarily relies on histopathology and clinical features. Comprehensive molecular profi...

Descripción completa

Detalles Bibliográficos
Autores principales: Gröschel, Stefan, Bommer, Martin, Hutter, Barbara, Budczies, Jan, Bonekamp, David, Heining, Christoph, Horak, Peter, Fröhlich, Martina, Uhrig, Sebastian, Hübschmann, Daniel, Geörg, Christina, Richter, Daniela, Pfarr, Nicole, Pfütze, Katrin, Wolf, Stephan, Schirmacher, Peter, Jäger, Dirk, von Kalle, Christof, Brors, Benedikt, Glimm, Hanno, Weichert, Wilko, Stenzinger, Albrecht, Fröhling, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5111004/
https://www.ncbi.nlm.nih.gov/pubmed/27900363
http://dx.doi.org/10.1101/mcs.a001180
_version_ 1782467788652150784
author Gröschel, Stefan
Bommer, Martin
Hutter, Barbara
Budczies, Jan
Bonekamp, David
Heining, Christoph
Horak, Peter
Fröhlich, Martina
Uhrig, Sebastian
Hübschmann, Daniel
Geörg, Christina
Richter, Daniela
Pfarr, Nicole
Pfütze, Katrin
Wolf, Stephan
Schirmacher, Peter
Jäger, Dirk
von Kalle, Christof
Brors, Benedikt
Glimm, Hanno
Weichert, Wilko
Stenzinger, Albrecht
Fröhling, Stefan
author_facet Gröschel, Stefan
Bommer, Martin
Hutter, Barbara
Budczies, Jan
Bonekamp, David
Heining, Christoph
Horak, Peter
Fröhlich, Martina
Uhrig, Sebastian
Hübschmann, Daniel
Geörg, Christina
Richter, Daniela
Pfarr, Nicole
Pfütze, Katrin
Wolf, Stephan
Schirmacher, Peter
Jäger, Dirk
von Kalle, Christof
Brors, Benedikt
Glimm, Hanno
Weichert, Wilko
Stenzinger, Albrecht
Fröhling, Stefan
author_sort Gröschel, Stefan
collection PubMed
description Identification of the tissue of origin in cancer of unknown primary (CUP) poses a diagnostic challenge and is critical for directing site-specific therapy. Currently, clinical decision-making in patients with CUP primarily relies on histopathology and clinical features. Comprehensive molecular profiling has the potential to contribute to diagnostic categorization and, most importantly, guide CUP therapy through identification of actionable lesions. We here report the case of an advanced-stage malignancy initially mimicking poorly differentiated soft-tissue sarcoma that did not respond to multiagent chemotherapy. Molecular profiling within a clinical whole-exome and transcriptome sequencing program revealed a heterozygous, highly amplified KRAS G12S mutation, compound-heterozygous TP53 mutation/deletion, high mutational load, and focal high-level amplification of Chromosomes 9p (including PDL1 [CD274] and JAK2) and 10p (including GATA3). Integrated analysis of molecular data and histopathology provided a rationale for immune checkpoint inhibitor (ICI) therapy with pembrolizumab, which resulted in rapid clinical improvement and a lasting partial remission. Histopathological analyses ruled out sarcoma and established the diagnosis of a poorly differentiated adenocarcinoma. Although neither histopathology nor molecular data were able to pinpoint the tissue of origin, our analyses established several differential diagnoses including triple-negative breast cancer (TNBC). We analyzed 157 TNBC samples from The Cancer Genome Atlas, revealing PDL1 copy number gains coinciding with excessive PDL1 mRNA expression in 24% of cases. Collectively, these results illustrate the impact of multidimensional tumor profiling in cases with nondescript histology and immunophenotype, show the predictive potential of PDL1 amplification for immune checkpoint inhibitors (ICIs), and suggest a targeted therapeutic strategy in Chromosome 9p24.1/PDL1-amplified cancers.
format Online
Article
Text
id pubmed-5111004
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Cold Spring Harbor Laboratory Press
record_format MEDLINE/PubMed
spelling pubmed-51110042016-11-29 Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with PDL1 amplification Gröschel, Stefan Bommer, Martin Hutter, Barbara Budczies, Jan Bonekamp, David Heining, Christoph Horak, Peter Fröhlich, Martina Uhrig, Sebastian Hübschmann, Daniel Geörg, Christina Richter, Daniela Pfarr, Nicole Pfütze, Katrin Wolf, Stephan Schirmacher, Peter Jäger, Dirk von Kalle, Christof Brors, Benedikt Glimm, Hanno Weichert, Wilko Stenzinger, Albrecht Fröhling, Stefan Cold Spring Harb Mol Case Stud Research Report Identification of the tissue of origin in cancer of unknown primary (CUP) poses a diagnostic challenge and is critical for directing site-specific therapy. Currently, clinical decision-making in patients with CUP primarily relies on histopathology and clinical features. Comprehensive molecular profiling has the potential to contribute to diagnostic categorization and, most importantly, guide CUP therapy through identification of actionable lesions. We here report the case of an advanced-stage malignancy initially mimicking poorly differentiated soft-tissue sarcoma that did not respond to multiagent chemotherapy. Molecular profiling within a clinical whole-exome and transcriptome sequencing program revealed a heterozygous, highly amplified KRAS G12S mutation, compound-heterozygous TP53 mutation/deletion, high mutational load, and focal high-level amplification of Chromosomes 9p (including PDL1 [CD274] and JAK2) and 10p (including GATA3). Integrated analysis of molecular data and histopathology provided a rationale for immune checkpoint inhibitor (ICI) therapy with pembrolizumab, which resulted in rapid clinical improvement and a lasting partial remission. Histopathological analyses ruled out sarcoma and established the diagnosis of a poorly differentiated adenocarcinoma. Although neither histopathology nor molecular data were able to pinpoint the tissue of origin, our analyses established several differential diagnoses including triple-negative breast cancer (TNBC). We analyzed 157 TNBC samples from The Cancer Genome Atlas, revealing PDL1 copy number gains coinciding with excessive PDL1 mRNA expression in 24% of cases. Collectively, these results illustrate the impact of multidimensional tumor profiling in cases with nondescript histology and immunophenotype, show the predictive potential of PDL1 amplification for immune checkpoint inhibitors (ICIs), and suggest a targeted therapeutic strategy in Chromosome 9p24.1/PDL1-amplified cancers. Cold Spring Harbor Laboratory Press 2016-11 /pmc/articles/PMC5111004/ /pubmed/27900363 http://dx.doi.org/10.1101/mcs.a001180 Text en © 2016 Gröschel et al.; Published by Cold Spring Harbor Laboratory Press http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/) , which permits reuse and redistribution, except for commercial purposes, provided that the original author and source are credited.
spellingShingle Research Report
Gröschel, Stefan
Bommer, Martin
Hutter, Barbara
Budczies, Jan
Bonekamp, David
Heining, Christoph
Horak, Peter
Fröhlich, Martina
Uhrig, Sebastian
Hübschmann, Daniel
Geörg, Christina
Richter, Daniela
Pfarr, Nicole
Pfütze, Katrin
Wolf, Stephan
Schirmacher, Peter
Jäger, Dirk
von Kalle, Christof
Brors, Benedikt
Glimm, Hanno
Weichert, Wilko
Stenzinger, Albrecht
Fröhling, Stefan
Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with PDL1 amplification
title Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with PDL1 amplification
title_full Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with PDL1 amplification
title_fullStr Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with PDL1 amplification
title_full_unstemmed Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with PDL1 amplification
title_short Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with PDL1 amplification
title_sort integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with pdl1 amplification
topic Research Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5111004/
https://www.ncbi.nlm.nih.gov/pubmed/27900363
http://dx.doi.org/10.1101/mcs.a001180
work_keys_str_mv AT groschelstefan integrationofgenomicsandhistologyrevisesdiagnosisandenableseffectivetherapyofrefractorycancerofunknownprimarywithpdl1amplification
AT bommermartin integrationofgenomicsandhistologyrevisesdiagnosisandenableseffectivetherapyofrefractorycancerofunknownprimarywithpdl1amplification
AT hutterbarbara integrationofgenomicsandhistologyrevisesdiagnosisandenableseffectivetherapyofrefractorycancerofunknownprimarywithpdl1amplification
AT budcziesjan integrationofgenomicsandhistologyrevisesdiagnosisandenableseffectivetherapyofrefractorycancerofunknownprimarywithpdl1amplification
AT bonekampdavid integrationofgenomicsandhistologyrevisesdiagnosisandenableseffectivetherapyofrefractorycancerofunknownprimarywithpdl1amplification
AT heiningchristoph integrationofgenomicsandhistologyrevisesdiagnosisandenableseffectivetherapyofrefractorycancerofunknownprimarywithpdl1amplification
AT horakpeter integrationofgenomicsandhistologyrevisesdiagnosisandenableseffectivetherapyofrefractorycancerofunknownprimarywithpdl1amplification
AT frohlichmartina integrationofgenomicsandhistologyrevisesdiagnosisandenableseffectivetherapyofrefractorycancerofunknownprimarywithpdl1amplification
AT uhrigsebastian integrationofgenomicsandhistologyrevisesdiagnosisandenableseffectivetherapyofrefractorycancerofunknownprimarywithpdl1amplification
AT hubschmanndaniel integrationofgenomicsandhistologyrevisesdiagnosisandenableseffectivetherapyofrefractorycancerofunknownprimarywithpdl1amplification
AT georgchristina integrationofgenomicsandhistologyrevisesdiagnosisandenableseffectivetherapyofrefractorycancerofunknownprimarywithpdl1amplification
AT richterdaniela integrationofgenomicsandhistologyrevisesdiagnosisandenableseffectivetherapyofrefractorycancerofunknownprimarywithpdl1amplification
AT pfarrnicole integrationofgenomicsandhistologyrevisesdiagnosisandenableseffectivetherapyofrefractorycancerofunknownprimarywithpdl1amplification
AT pfutzekatrin integrationofgenomicsandhistologyrevisesdiagnosisandenableseffectivetherapyofrefractorycancerofunknownprimarywithpdl1amplification
AT wolfstephan integrationofgenomicsandhistologyrevisesdiagnosisandenableseffectivetherapyofrefractorycancerofunknownprimarywithpdl1amplification
AT schirmacherpeter integrationofgenomicsandhistologyrevisesdiagnosisandenableseffectivetherapyofrefractorycancerofunknownprimarywithpdl1amplification
AT jagerdirk integrationofgenomicsandhistologyrevisesdiagnosisandenableseffectivetherapyofrefractorycancerofunknownprimarywithpdl1amplification
AT vonkallechristof integrationofgenomicsandhistologyrevisesdiagnosisandenableseffectivetherapyofrefractorycancerofunknownprimarywithpdl1amplification
AT brorsbenedikt integrationofgenomicsandhistologyrevisesdiagnosisandenableseffectivetherapyofrefractorycancerofunknownprimarywithpdl1amplification
AT glimmhanno integrationofgenomicsandhistologyrevisesdiagnosisandenableseffectivetherapyofrefractorycancerofunknownprimarywithpdl1amplification
AT weichertwilko integrationofgenomicsandhistologyrevisesdiagnosisandenableseffectivetherapyofrefractorycancerofunknownprimarywithpdl1amplification
AT stenzingeralbrecht integrationofgenomicsandhistologyrevisesdiagnosisandenableseffectivetherapyofrefractorycancerofunknownprimarywithpdl1amplification
AT frohlingstefan integrationofgenomicsandhistologyrevisesdiagnosisandenableseffectivetherapyofrefractorycancerofunknownprimarywithpdl1amplification